Company
Clarus Therapeutics Holdings, Inc.
Headquarters: Northbrook, IL, United States
CEO: Dr. Robert E. Dudley Ph.D.
Clarus Therapeutics Holdings, Inc. Categories
United States Healthcare Drug Manufacturers—GeneralUnited States Healthcare United States Drug Manufacturers—General
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
| AbbVie | $285.06 B |
| Roche | $240.44 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Clarus Therapeutics Holdings, Inc. has the following listings and related stock indices.
Stock: NASDAQ: CRXT wb_incandescent